Efficacy of trastuzumab combined with cisplatin and docetaxel on gastric cardia carcinoma and its influence on HER2 and cyclin D1 expressions

Minerva Med. 2021 Jun;112(3):402-403. doi: 10.23736/S0026-4806.19.06184-6. Epub 2019 Jul 5.

Authors

Huiyan Tang¹, Yan Zhao², Wen Xiong³, Lulu Liu⁴, Chuanyu Ma⁵

Affiliations

¹ Department of Oncology, Xintai People's Hospital, Xintai, China.
² Department of Pathology, Liaocheng Dongchangfu People's Hospital, Liaocheng, China.
³ Department of Pathology, Affiliated hospital of Weifang Medical University, Weifang, China.
⁴ Department of Pathology, Tai'an Maternity and Child Care Hospital, Tai'an, China.
⁵ Department of Anus-Intestines, Linyi Central Hospital, Linyi, China - 1652577449@qq.com.

PMID: 31282137
DOI: 10.23736/S0026-4806.19.06184-6

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents, Immunological / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma / drug therapy*
Carcinoma / metabolism
Cardia* / metabolism
Cisplatin / administration & dosage
Cyclin D1 / metabolism*
Docetaxel / administration & dosage
Humans
Neoplasm Proteins / metabolism
Receptor, ErbB-2 / metabolism*
Stomach Neoplasms / drug therapy*
Stomach Neoplasms / metabolism
Trastuzumab / administration & dosage

Substances

Antineoplastic Agents, Immunological
Neoplasm Proteins
Cyclin D1
Docetaxel
Receptor, ErbB-2
Trastuzumab
Cisplatin